Literature DB >> 25548478

Molecular diagnosis and therapy for occult peritoneal metastasis in gastric cancer patients.

Shunsuke Kagawa1, Kunitoshi Shigeyasu1, Michihiro Ishida1, Megumi Watanabe1, Hiroshi Tazawa1, Takeshi Nagasaka1, Yasuhiro Shirakawa1, Toshiyoshi Fujiwara1.   

Abstract

To apply an individualized oncological approach to gastric cancer patients, the accurate diagnosis of disease entities is required. Peritoneal metastasis is the most frequent mode of metastasis in gastric cancer, and the tumor-node-metastasis classification includes cytological detection of intraperitoneal cancer cells as part of the staging process, denoting metastatic disease. The accuracy of cytological diagnosis leaves room for improvement; therefore, highly sensitive molecular diagnostics, such as an enzyme immunoassay, reverse transcription polymerase chain reaction, and virus-guided imaging, have been developed to detect minute cancer cells in the peritoneal cavity. Molecular targeting therapy has also been spun off from basic research in the past decade. Although conventional cytology is still the mainstay, novel approaches could serve as practical complementary diagnostics to cytology in near future.

Entities:  

Keywords:  Carcinoembryonic antigen; Cytology; Gastric cancer; Molecular diagnostic techniques; Peritoneal lavage; Reverse transcriptase polymerase chain reaction

Mesh:

Substances:

Year:  2014        PMID: 25548478      PMCID: PMC4273130          DOI: 10.3748/wjg.v20.i47.17796

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  67 in total

1.  Prognostic significance of carcinoembryonic antigen levels in peritoneal washes in patients with gastric cancer.

Authors:  N Abe; T Watanabe; H Toda; H Machida; K Suzuki; T Masaki; T Mori; M Sugiyama; Y Atomi; Y Nakaya
Journal:  Am J Surg       Date:  2001-04       Impact factor: 2.565

2.  Assessment of the exfoliation of tumor cells into the body cavities.

Authors:  G E MOORE; K SAKO; T KONDO; J BADILLO; E BURKE
Journal:  Surg Gynecol Obstet       Date:  1961-04

Review 3.  A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer.

Authors:  Pierre-Anthony Leake; Roberta Cardoso; Rajini Seevaratnam; Laercio Lourenco; Lucy Helyer; Alyson Mahar; Corwyn Rowsell; Natalie G Coburn
Journal:  Gastric Cancer       Date:  2011-08-02       Impact factor: 7.370

4.  Japanese gastric cancer treatment guidelines 2010 (ver. 3).

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

5.  Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3).

Authors:  Michael Jäger; Alexandra Schoberth; Peter Ruf; Juergen Hess; Michael Hennig; Barbara Schmalfeldt; Pauline Wimberger; Michael Ströhlein; Bettina Theissen; Markus M Heiss; Horst Lindhofer
Journal:  Cancer Res       Date:  2011-11-01       Impact factor: 12.701

6.  Ascites analysis by a microfluidic chip allows tumor-cell profiling.

Authors:  Vanessa M Peterson; Cesar M Castro; Jaehoon Chung; Nathan C Miller; Adeeti V Ullal; Maria D Castano; Richard T Penson; Hakho Lee; Michael J Birrer; Ralph Weissleder
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

7.  Detection of micrometastases in peritoneal washings of gastric cancer patients by the reverse transcriptase polymerase chain reaction.

Authors:  Kimberly Moore Dalal; Yanghee Woo; Kaitlyn Kelly; Charles Galanis; Mithat Gonen; Yuman Fong; Daniel G Coit
Journal:  Gastric Cancer       Date:  2009-01-08       Impact factor: 7.370

8.  Clinical significance of telomerase activity in peritoneal lavage fluid from patients with gastric cancer and its relationship with cellular proliferation.

Authors:  Ming-Xu Da; Xiao-Ting Wu; Tian-Kang Guo; Zi-Guang Zhao; Ting Luo; Kun Qian; Ming-Ming Zhang; Jie Wang
Journal:  World J Gastroenterol       Date:  2007-06-14       Impact factor: 5.742

9.  Prognostic value of CEA and CK20 mRNA in the peritoneal lavage fluid of patients undergoing curative surgery for gastric cancer.

Authors:  Akihiro Takata; Yukinori Kurokawa; Yoshiyuki Fujiwara; Yurika Nakamura; Tsuyoshi Takahashi; Makoto Yamasaki; Hiroshi Miyata; Kiyokazu Nakajima; Shuji Takiguchi; Masaki Mori; Yuichiro Doki
Journal:  World J Surg       Date:  2014-05       Impact factor: 3.352

10.  Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel.

Authors:  Savtaj S Brar; Alyson L Mahar; Lucy K Helyer; Carol Swallow; Calvin Law; Lawrence Paszat; Rajini Seevaratnam; Roberta Cardoso; Robin McLeod; Matthew Dixon; Lavanya Yohanathan; Laercio G Lourenco; Alina Bocicariu; Tanios Bekaii-Saab; Ian Chau; Neal Church; Daniel Coit; Christopher H Crane; Craig Earle; Paul Mansfield; Norman Marcon; Thomas Miner; Sung Hoon Noh; Geoff Porter; Mitchell C Posner; Vivek Prachand; Takeshi Sano; Cornelis van de Velde; Sandra Wong; Natalie G Coburn
Journal:  JAMA Surg       Date:  2014-01       Impact factor: 14.766

View more
  16 in total

1.  Long non-coding RNA AB007962 is downregulated in gastric cancer and associated with poor prognosis.

Authors:  Jia-Jun Wang; Yu-Chong Yang; Yong-Xi Song; Peng Gao; Jing-Xu Sun; Xiao-Wan Chen; Bin Ma; Zhen-Ning Wang
Journal:  Oncol Lett       Date:  2018-07-18       Impact factor: 2.967

2.  TRIM58 suppresses the tumor growth in gastric cancer by inactivation of β-catenin signaling via ubiquitination.

Authors:  Xiaowen Liu; Ziwen Long; Hong Cai; Shengjia Yu; Jianghong Wu
Journal:  Cancer Biol Ther       Date:  2019-11-21       Impact factor: 4.742

3.  The GAS5/miR-222 Axis Regulates Proliferation of Gastric Cancer Cells Through the PTEN/Akt/mTOR Pathway.

Authors:  Yanhua Li; Junjiao Gu; Hong Lu
Journal:  Dig Dis Sci       Date:  2017-11-02       Impact factor: 3.199

4.  TRIM25 blockade by RNA interference inhibited migration and invasion of gastric cancer cells through TGF-β signaling.

Authors:  Zhenya Zhu; Yong Wang; Chunhui Zhang; Shiyong Yu; Qi Zhu; Kun Hou; Bo Yan
Journal:  Sci Rep       Date:  2016-01-12       Impact factor: 4.379

5.  Tanshinone IIA inhibits cell proliferation and tumor growth by downregulating STAT3 in human gastric cancer.

Authors:  Yongjun Zhang; Shuguang Guo; Jian Fang; Bojian Peng; Yuan Zhang; Tiansheng Cao
Journal:  Exp Ther Med       Date:  2018-08-02       Impact factor: 2.447

6.  Long non-coding RNA MEG3 functions as a competing endogenous RNA to regulate gastric cancer progression.

Authors:  Weizhao Peng; Shuang Si; Qingxia Zhang; Chaofeng Li; Fang Zhao; Fang Wang; Jia Yu; Ren Ma
Journal:  J Exp Clin Cancer Res       Date:  2015-08-08

7.  PRL-3 promotes the peritoneal metastasis of gastric cancer through the PI3K/Akt signaling pathway by regulating PTEN.

Authors:  Jianbo Xiong; Zhengrong Li; Yang Zhang; Daojiang Li; Guoyang Zhang; Xianshi Luo; Zhigang Jie; Yi Liu; Yi Cao; Zhibiao Le; Shengxing Tan; Wenyu Zou; Peitao Gong; Lingyu Qiu; Yuanyuan Li; Huan Wang; Heping Chen
Journal:  Oncol Rep       Date:  2016-08-23       Impact factor: 3.906

8.  REG4 promotes peritoneal metastasis of gastric cancer through GPR37.

Authors:  Hexiao Wang; Lei Hu; Mingde Zang; Baogui Zhang; Yantao Duan; Zhiyuan Fan; Jianfang Li; Liping Su; Min Yan; Zhenggang Zhu; Bingya Liu; Qiumeng Yang
Journal:  Oncotarget       Date:  2016-05-10

9.  Integrated fluorescent cytology with nano-biologics in peritoneally disseminated gastric cancer.

Authors:  Megumi Watanabe; Shunsuke Kagawa; Kazuya Kuwada; Yuuri Hashimoto; Kunitoshi Shigeyasu; Michihiro Ishida; Shuichi Sakamoto; Atene Ito; Satoru Kikuchi; Shinji Kuroda; Hiroyuki Kishimoto; Shuta Tomida; Ryuichi Yoshida; Hiroshi Tazawa; Yasuo Urata; Toshiyoshi Fujiwara
Journal:  Cancer Sci       Date:  2018-09-23       Impact factor: 6.716

10.  TRIM32 promotes cell proliferation and invasion by activating β-catenin signalling in gastric cancer.

Authors:  Changming Wang; Jiapeng Xu; Hongbing Fu; Yu Zhang; Xin Zhang; Dejun Yang; Zhenxin Zhu; Ziran Wei; Zunqi Hu; Ronglin Yan; Qingping Cai
Journal:  J Cell Mol Med       Date:  2018-08-05       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.